Novartis and collaborators discover novel antimalarial drug candidate
Read the Novartis Media Release
- New antimalarial drug candidate with novel mechanism of action has the potential to rapidly clear a Plasmodium infection upon administration of a single oral dose, as published in Science
- Novartis led collaboration includes The Scripps Research Institute, the Swiss Tropical and Public Health Institute, with major support from the Wellcome Trust, Medicines for Malaria Venture, the Agency for Science, Technology and Research (A*STAR), Singapore, as well as the U.S. government.
- In 2008, there were 247 million cases of malaria and nearly one million deaths – mostly among children living in Africa.
Read more on foundation support
Research at NIBR
Our global research efforts begin and end with the patient.
